Safety and Efficacy of Subcutaneous Daratumumab in Systemic AL Amyloidosis
Michael Sang Hughes, Suzanne Lentzsch Department of Hematology-Oncology, Columbia University Irving Medical Center, New York, NY, USACorrespondence: Suzanne Lentzsch, Department of Hematology-Oncology, Columbia University Irving Medical Center, MH-6GN 435, 161 Fort Washington Ave, New York, NY, 1003...
Saved in:
Main Authors: | Hughes MS (Author), Lentzsch S (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2023-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Time for newer approach in age-old AIHA: Daratumumab?
by: Sigbjørn Berentsen, et al.
Published: (2024) -
Subcutaneous scalp nodule as the presenting symptom of systemic light-chain amyloidosis
by: Joseph Tadros, et al.
Published: (2018) -
Venetoclax and Daratumumab combination treatment demonstrates pre-clinical efficacy in mouse models of Acute Myeloid Leukemia
by: Jayna J Mistry, et al.
Published: (2021) -
Economic Evaluation of Adding Daratumumab to Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma
by: Yi L, et al.
Published: (2024) -
Cost-Effectiveness Analysis of Adding Daratumumab to Bortezomib, Melphalan, and Prednisone for Untreated Multiple Myeloma
by: Yaohua Cao, et al.
Published: (2021)